OnCo

Sign in to keep your watchlist

Your watched pages live in this browser. Sign in with an email link and OnCo keeps the same list on every device you use. Only your email address and your watchlist are stored.

Living with cancer·Standard of care

Indolent and smouldering systemic mastocytosis: the decisions you may face

Cancer page →Second-opinion finder →

5 treatment settings, 3 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

2 options

Serum tryptase, KIT D816V testing in peripheral blood, bone marrow biopsy with flow cytometry, tryptase gene copy number, bone density scan and screening for B and C findings.

Guideline
NCCN Guidelines: Systemic Mastocytosis
The options, in plain words
Histopathology & immunohistochemistryStandard of care

Histopathology means looking at cancer cells under a microscope, and immunohistochemistry stains them for specific proteins. Together they are still the foundation of every diagnosis.

  • Cheap, fast, universal
  • Companion diagnostic for most targeted drugs
Multiparameter flow cytometry MRDStandard of care

Flow cytometry MRD counts leukaemia cells in the bone marrow one at a time by their surface proteins, down to one in ten thousand.

  • Broadly applicable, fast (same day)
  • Works without a molecular marker
Also referenced:KITDriver mutation
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
Histopathology & immunohistochemistry
  • Subjective scoring
  • Single-site sampling misses heterogeneity
Multiparameter flow cytometry MRD
  • Operator and lab dependent
  • Sensitivity below molecular methods; immunophenotype shift after therapy
Questions to ask about this decision
  1. Between Histopathology & immunohistochemistry and Multiparameter flow cytometry MRD, which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (NCCN Guidelines: Systemic Mastocytosis), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (diagnosis), which of the standard options do you recommend and why?
    Why: Guideline options include: Serum tryptase, KIT D816V testing in peripheral blood, bone marrow biopsy with flow cytometry, tryptase gene copy number, bone density scan and screening for B and C findings.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

Symptom control

One path named

H1 and H2 antihistamines, cromoglicate, leukotriene antagonists, proton-pump inhibitors; omalizumab for recurrent anaphylaxis; adrenaline autoinjectors for all; venom immunotherapy after sting anaphylaxis; bisphosphonates for osteoporosis.

Guideline
NCCN Guidelines: Systemic Mastocytosis
The path, in plain words
Electronic patient-reported outcome (ePRO) symptom monitoringEstablished

Patients report symptoms weekly through an app or web form, and nurses respond to alerts. Randomised trials showed this simple system improved quality of life, cut emergency visits and, in one trial, extended survival by five months.

  • Randomised evidence for quality of life, utilisation and survival
  • Low cost; scalable through existing portals
  • Standardised instruments (PRO-CTCAE, ESAS)
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
Electronic patient-reported outcome (ePRO) symptom monitoring
  • Requires responsive nursing capacity
  • Digital literacy and language barriers
  • Alert fatigue if thresholds poorly set
Questions to ask about this decision
  1. Is Electronic patient-reported outcome (ePRO) symptom monitoring the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
    Why: A single standard does not mean a single choice; timing and trials are decisions too.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (NCCN Guidelines: Systemic Mastocytosis), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (symptom control), which of the standard options do you recommend and why?
    Why: Guideline options include: H1 and H2 antihistamines, cromoglicate, leukotriene antagonists, proton-pump inhibitors; omalizumab for recurrent anaphylaxis; adrenaline autoinjectors for all; venom immunotherapy after sting anaphylaxis; bisphosphonates for osteoporosis.

Add these to your appointment list, or take the full question set for this cancer.

Special situations

Moderate to severe symptoms despite supportive care

4 optionsCompare side by side →

Avapritinib 25 mg daily (PIONEER, approved 2023), avoided when platelets are below 50 x 10^9/L; cladribine or interferon alfa as older cytoreductive options.

Guideline
NCCN Guidelines: Systemic Mastocytosis
The options, in plain words
AvapritinibApprovedSmall-molecule kinase inhibitor (PDGFRA D842V / KIT)

Avapritinib is the first drug for GIST driven by the PDGFRA D842V mutation, which resists every other kinase inhibitor; it is also approved for systemic mastocytosis.

CladribineApprovedPurine nucleoside analogue

A one-week infusion that puts most people with hairy cell leukaemia into remission for years; also used in multiple sclerosis in tablet form.

Interferon alfa-2a/2bHistoricRecombinant type I interferon (cytokine)

Interferon alfa was the first biologic cancer drug (1986). It treated hairy cell leukaemia, CML, melanoma, kidney cancer and Kaposi sarcoma, and has been replaced almost everywhere by better-tolerated agents.

Small-molecule kinase inhibitorsStandard of care

Pills that block the specific enzyme a cancer relies on. Imatinib in 2001 proved a cancer could be switched off by design.

  • Oral, outpatient
  • Dramatic responses in oncogene-addicted cancers
The evidence behind it
The main trade-offs on record
Small-molecule kinase inhibitors
  • Near-universal resistance in metastatic disease
  • Off-target toxicities
Questions to ask about this decision
  1. Between Avapritinib, Cladribine, Interferon alfa-2a/2b and the other options, which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. How closely do I match the people in (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo , and does that change what the results mean for me?
    Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
  4. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  5. Does your recommendation follow the current guideline (NCCN Guidelines: Systemic Mastocytosis), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  6. For my situation (moderate to severe symptoms despite supportive care), which of the standard options do you recommend and why?
    Why: Guideline options include: Avapritinib 25 mg daily (PIONEER, approved 2023), avoided when platelets are below 50 x 10^9/L; cladribine or interferon alfa as older cytoreductive options.
  7. Am I a candidate for Avapritinib, Cladribine, Interferon alfa-2a/2b, and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
  8. How do the results of (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo apply to someone like me?
    Why: Trial populations differ from individual patients; ask how closely you match.

Add these to your appointment list, or take the full question set for this cancer.

2 optionsCompare side by side →

Elenestinib (HARBOR) and bezuclastinib (Summit) as more selective KIT D816V inhibitors.

Guideline
NCCN Guidelines: Systemic Mastocytosis
The options, in plain words
ElenestinibPhase 3small molecule

Elenestinib is an experimental small-molecule drug from Blueprint Medicines in phase 3 trials for systemic mastocytosis, with its target not yet stated publicly.

BezuclastinibPhase 3small molecule

Bezuclastinib is an experimental small-molecule drug from Cogent Biosciences in phase 3 trials for gastrointestinal stromal tumour, aimed at KIT and MET.

The evidence behind it
The main trade-offs on record

No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.

Questions to ask about this decision
  1. Between Elenestinib and Bezuclastinib, which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. How closely do I match the people in (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis and (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis, and does that change what the results mean for me?
    Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
  4. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  5. Does your recommendation follow the current guideline (NCCN Guidelines: Systemic Mastocytosis), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  6. For my situation (trials), which of the standard options do you recommend and why?
    Why: Guideline options include: Elenestinib (HARBOR) and bezuclastinib (Summit) as more selective KIT D816V inhibitors.
  7. Am I a candidate for Elenestinib, Bezuclastinib, and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
  8. How do the results of (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis and (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis apply to someone like me?
    Why: Trial populations differ from individual patients; ask how closely you match.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

Monitoring

One path named

Tryptase, KIT allele burden and blood count yearly; bone density; marrow re-examination only if progression is suspected.

Guideline
NCCN Guidelines: Systemic Mastocytosis
The path, in plain words
Liquid biopsy (ctDNA)Standard of care

A blood test that reads fragments of DNA shed by the tumour, so you can genotype or monitor cancer without a needle in the tumour.

  • Minimally invasive, repeatable
  • Whole-body clonal picture
Also referenced:Molecular response (MMR, MR4, treatment-free remission)
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
Liquid biopsy (ctDNA)
  • Low shedding in some tumours (brain, early-stage)
  • Clonal haematopoiesis false positives
Questions to ask about this decision
  1. Is Liquid biopsy (ctDNA) the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
    Why: A single standard does not mean a single choice; timing and trials are decisions too.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (NCCN Guidelines: Systemic Mastocytosis), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (monitoring), which of the standard options do you recommend and why?
    Why: Guideline options include: Tryptase, KIT allele burden and blood count yearly; bone density; marrow re-examination only if progression is suspected.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.